Heino Stass
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Heino Stass has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
D. Kubitza
BAYER AG, Pharma Research Centre, ICP, Wuppertal, Germany
6 shared publicationsDagmar Kubitza
Bayer AG
4 shared publicationsA. Dalhoff
Bayer AG
3 shared publicationsH. Delesen
BAYER AG, Pharma Research Centre, ICP, Wuppertal, Germany
3 shared publicationsHeinz Delesen
Bayer AG
2 shared publicationsJan-Georg Möller
Bayer AG
2 shared publications
Latest Publications
- 1 May 2005
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 59 (5) , 536-541
Influence of activated charcoal on the pharmacokinetics of moxifloxacin following intravenous and oral administration of a 400 mg single dose to healthy males
To evaluate the extent to which enterohepatic recycling circulation contributes to moxifloxacin bioavailability in healthy, males by administration of activated charcoal and to evaluate the efficacy of activated charcoal administration in decreasing systemic concentrations of moxifloxacin in the event of overdose.Nine healthy males, mean age 34 years (range 23-45 years) participated in a single centre, randomized, nonplacebo-controlled, three way crossover study. The pharmacokinetics of moxifloxacin in plasma and urine were determined for up to 96 h following a 400 mg single dose randomly administered on three separate occasions with a minimum washout phase of 1 week. Treatment A was 400 mg moxifloxacin IV as a 1 h infusion, treatment B was 400 mg moxifloxacin IV as a 1 h infusion with oral activated charcoal (5 g directly before the start of the infusion, 5 g immediately after the end of the infusion, and 10 g at 2, 4 and 8 h after the start of the infusion), treatment C was 400 mg oral moxifloxacin with activated charcoal (10 g 15 min before and at 2, 4 and 8 h after drug administration). The subjects underwent a series of clinical and laboratory tests.Single 400 mg doses of moxifloxacin (PO and/or IV) were safe and well tolerated. The bioavailability of moxifloxacin was significantly decreased when given with charcoal (AUC = 35.5 (IV reference) vs 5.40 (PO) vs 28.5 (IV) mg l(-1) h). Concurrently peak concentrations were lowered C(max) = 3.38 (IV reference) vs 0.62(PO) vs 2.97 (IV) mg l(-1)) by approximately 85% (P < 0.05) following oral administration and by 20% after IV treatment (P < 0.05). Bioavailability amounted to 15.4% (95% confidence interval 9.6, 25.0%) for treatment B while it was 80.4% (95% confidence interval 76.3.6, 84.6%) for treatment C. Terminal half-lives were not affected. The kinetics of urinary excretion corroborated these findings.The results of this study show that moxifloxacin undergoes pronounced enteric recycling after systemic uptake. In addition, these findings confirm that activated charcoal may be useful in treating moxifloxacin overdose by preventing its absorption.
- 1 May 2005
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 59 (5) , 536-541
Influence of activated charcoal on the pharmacokinetics of moxifloxacin following intravenous and oral administration of a 400 mg single dose to healthy males
To evaluate the extent to which enterohepatic recycling circulation contributes to moxifloxacin bioavailability in healthy, males by administration of activated charcoal and to evaluate the efficacy of activated charcoal administration in decreasing systemic concentrations of moxifloxacin in the event of overdose.Nine healthy males, mean age 34 years (range 23-45 years) participated in a single centre, randomized, nonplacebo-controlled, three way crossover study. The pharmacokinetics of moxifloxacin in plasma and urine were determined for up to 96 h following a 400 mg single dose randomly administered on three separate occasions with a minimum washout phase of 1 week. Treatment A was 400 mg moxifloxacin IV as a 1 h infusion, treatment B was 400 mg moxifloxacin IV as a 1 h infusion with oral activated charcoal (5 g directly before the start of the infusion, 5 g immediately after the end of the infusion, and 10 g at 2, 4 and 8 h after the start of the infusion), treatment C was 400 mg oral moxifloxacin with activated charcoal (10 g 15 min before and at 2, 4 and 8 h after drug administration). The subjects underwent a series of clinical and laboratory tests.Single 400 mg doses of moxifloxacin (PO and/or IV) were safe and well tolerated. The bioavailability of moxifloxacin was significantly decreased when given with charcoal (AUC = 35.5 (IV reference) vs 5.40 (PO) vs 28.5 (IV) mg l(-1) h). Concurrently peak concentrations were lowered C(max) = 3.38 (IV reference) vs 0.62(PO) vs 2.97 (IV) mg l(-1)) by approximately 85% (P < 0.05) following oral administration and by 20% after IV treatment (P < 0.05). Bioavailability amounted to 15.4% (95% confidence interval 9.6, 25.0%) for treatment B while it was 80.4% (95% confidence interval 76.3.6, 84.6%) for treatment C. Terminal half-lives were not affected. The kinetics of urinary excretion corroborated these findings.The results of this study show that moxifloxacin undergoes pronounced enteric recycling after systemic uptake. In addition, these findings confirm that activated charcoal may be useful in treating moxifloxacin overdose by preventing its absorption.
- 1 January 2004
- Published by Dustri-Verlag Dr. Karl Feistle in Int. Journal of Clinical Pharmacology and Therapeutics
- Vol. 42 (1) , 23-30
Pharmacokinetics of moxifloxacin are not influenced by a 7-day pretreatment with 200 mg oral itraconazole given once a day in healthy subjects
The primary objective of this interaction study was to confirm preclinical data suggesting that moxifloxacin is not metabolized by CYP 450 isozymes. Itraconazole, a strong CYP 3A4 inhibitor, was used as comedication. Twelve healthy male subjects were enrolled in this randomized study using 400 mg of oral moxifloxacin (MXF) administered alone and on the 7th day of a 9-day treatment regimen with itraconazole (ITR) 200 mg p.o., o.d. In addition to the assessment of safety and tolerability, non-compartmental pharmacokinetics of moxifloxacin, itraconazole and their respective metabolites were analyzed using plasma concentrations obtained using HPLC. All treatment regimens were safe and well-tolerated. No interaction with itraconazole was observed for moxifloxacin (relative bioavailability: 111.6% (90% CI 106.5 to 117.0%), C(max) ratio: 103.7% (84.8-126.9%) and its sulfometabolite (Ml) (AUC ratio: 107.7% (95.6, 121.4%), C(max) ratio: 105.8% (89.9-124.5%)). There was a 30% decrease in AUC with M2 moxifloxacin metabolite (glucuronide) accompanied by an approximately 54% increase in renal excretion, which may be due to changes in phase 2 metabolism and/or transport mechanisms altered by itraconazole. Exposure (AUC) to itraconazole and its hydroxymetabolite were marginally altered by moxifloxacin (AUC +5% for itraconazole and -5% for hydroxy-itraconazole (OH-ITR)) indicating the absence of a clinically relevant influence of moxifloxacin on itraconazole. Mean peak concentrations in plasma (C(max)) were reduced for ITR and OH-ITR by approximately 14% and 18%, respectively, when administered concomitantly with moxifloxacin. This was attributed to the sensitivity of itraconazole absorption to changes in gastric physiology (pH, gastric transit, administration after fasting) and was deemed as clinically irrelevant. Results of this study indicate that moxifloxacin is not a substrate for CYP 450 3A4 isozymes confirming previous preclinical in vitro data. Moxifloxacin can therefore be safely coadministered with CYP 3A4 inhibitors without the need for dose adjustment. No clinically relevant changes in the pharmacokinetics of itraconazole were observed during the study.
- 1 January 2004
- Published by Dustri-Verlag Dr. Karl Feistle in Int. Journal of Clinical Pharmacology and Therapeutics
- Vol. 42 (1) , 23-30
Pharmacokinetics of moxifloxacin are not influenced by a 7-day pretreatment with 200 mg oral itraconazole given once a day in healthy subjects
The primary objective of this interaction study was to confirm preclinical data suggesting that moxifloxacin is not metabolized by CYP 450 isozymes. Itraconazole, a strong CYP 3A4 inhibitor, was used as comedication. Twelve healthy male subjects were enrolled in this randomized study using 400 mg of oral moxifloxacin (MXF) administered alone and on the 7th day of a 9-day treatment regimen with itraconazole (ITR) 200 mg p.o., o.d. In addition to the assessment of safety and tolerability, non-compartmental pharmacokinetics of moxifloxacin, itraconazole and their respective metabolites were analyzed using plasma concentrations obtained using HPLC. All treatment regimens were safe and well-tolerated. No interaction with itraconazole was observed for moxifloxacin (relative bioavailability: 111.6% (90% CI 106.5 to 117.0%), C(max) ratio: 103.7% (84.8-126.9%) and its sulfometabolite (Ml) (AUC ratio: 107.7% (95.6, 121.4%), C(max) ratio: 105.8% (89.9-124.5%)). There was a 30% decrease in AUC with M2 moxifloxacin metabolite (glucuronide) accompanied by an approximately 54% increase in renal excretion, which may be due to changes in phase 2 metabolism and/or transport mechanisms altered by itraconazole. Exposure (AUC) to itraconazole and its hydroxymetabolite were marginally altered by moxifloxacin (AUC +5% for itraconazole and -5% for hydroxy-itraconazole (OH-ITR)) indicating the absence of a clinically relevant influence of moxifloxacin on itraconazole. Mean peak concentrations in plasma (C(max)) were reduced for ITR and OH-ITR by approximately 14% and 18%, respectively, when administered concomitantly with moxifloxacin. This was attributed to the sensitivity of itraconazole absorption to changes in gastric physiology (pH, gastric transit, administration after fasting) and was deemed as clinically irrelevant. Results of this study indicate that moxifloxacin is not a substrate for CYP 450 3A4 isozymes confirming previous preclinical in vitro data. Moxifloxacin can therefore be safely coadministered with CYP 3A4 inhibitors without the need for dose adjustment. No clinically relevant changes in the pharmacokinetics of itraconazole were observed during the study.
- 1 March 2002
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 53 (3) , 232-237
Pharmacokinetics of moxifloxacin, a novel 8‐methoxy‐quinolone, in patients with renal dysfunction
Aims To evaluate the influence of impaired renal function on the plasma and urinary pharmacokinetics of moxifloxacin, a novel 8‐methoxy‐quinolone antibacterial drug.Methods Twenty male and 12 female subjects (8 healthy subjects, 24 patients with impaired renal function), 18–75 years of age were investigated in parallel fashion with four groups stratified according to creatinine clearance (CLCR; n=8 for each group). The pharmacokinetics of moxifloxacin and the metabolites M1 (sulphonate metabolite) and M2 (glucuronide) in plasma and urine were determined repeatedly up to 96 h after single oral doses of 400 mg. Patients were monitored intensively with regard to clinical and laboratory safety and tolerability.Results Single doses of 400 mg moxifloxacin were safe and well tolerated. The urinary excretion of moxifloxacin (Aeur, P: 0.0002) and renal clearance (CLR, PCR, mean Cmax was slightly reduced (Cmax‐ratio 85.0%, 90% CI 67.9, 106.4% severe renal impairment vs healthy subjects) but the AUC was unchanged even in severe renal impairment (AUC‐ratio 101.3%, 90% CI 79.7, 128.6%). The mean AUC of the N‐sulphonate M1 was slightly increased (by about 53% for the most severe disease) by impaired renal function, but there was no significant correlation between individual AUC and CLCR, whilst Aeur and CLR were significantly correlated with CLCR. In contrast, for the acylglucuronide M2, Aeur (P: 0.0026), CLR (PP: 0.0011) were directly correlated with CLCR.Conclusions Renal dysfunction had little effect on the plasma pharmacokinetics of either moxifloxacin or metabolite M1, although their renal clearance and urinary excretion were reduced. In contrast renal dysfunction did result in changes in the plasma pharmacokinetics of metabolite M2, causing greater and longer exposure. However the extent of these changes is unlikely to be of clinical relevance.
- 1 March 2002
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 53 (3) , 232-237
Pharmacokinetics of moxifloxacin, a novel 8‐methoxy‐quinolone, in patients with renal dysfunction
Aims To evaluate the influence of impaired renal function on the plasma and urinary pharmacokinetics of moxifloxacin, a novel 8‐methoxy‐quinolone antibacterial drug.Methods Twenty male and 12 female subjects (8 healthy subjects, 24 patients with impaired renal function), 18–75 years of age were investigated in parallel fashion with four groups stratified according to creatinine clearance (CLCR; n=8 for each group). The pharmacokinetics of moxifloxacin and the metabolites M1 (sulphonate metabolite) and M2 (glucuronide) in plasma and urine were determined repeatedly up to 96 h after single oral doses of 400 mg. Patients were monitored intensively with regard to clinical and laboratory safety and tolerability.Results Single doses of 400 mg moxifloxacin were safe and well tolerated. The urinary excretion of moxifloxacin (Aeur, P: 0.0002) and renal clearance (CLR, PCR, mean Cmax was slightly reduced (Cmax‐ratio 85.0%, 90% CI 67.9, 106.4% severe renal impairment vs healthy subjects) but the AUC was unchanged even in severe renal impairment (AUC‐ratio 101.3%, 90% CI 79.7, 128.6%). The mean AUC of the N‐sulphonate M1 was slightly increased (by about 53% for the most severe disease) by impaired renal function, but there was no significant correlation between individual AUC and CLCR, whilst Aeur and CLR were significantly correlated with CLCR. In contrast, for the acylglucuronide M2, Aeur (P: 0.0026), CLR (PP: 0.0011) were directly correlated with CLCR.Conclusions Renal dysfunction had little effect on the plasma pharmacokinetics of either moxifloxacin or metabolite M1, although their renal clearance and urinary excretion were reduced. In contrast renal dysfunction did result in changes in the plasma pharmacokinetics of metabolite M2, causing greater and longer exposure. However the extent of these changes is unlikely to be of clinical relevance.
- Open Access
- 15 March 2001
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 32 (Supplement) , S47-S50
Profile of Moxifloxacin Drug Interactions
We report a brief description of the interaction profile of moxifloxacin. After oral administration, the absorption of moxifloxacin was unaffected by
- 15 March 2001
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 32 (Supplement) , S47-S50
Open AccessProfile of Moxifloxacin Drug Interactions
We report a brief description of the interaction profile of moxifloxacin. After oral administration, the absorption of moxifloxacin was unaffected by
- 1 January 2001
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 40 (Supplement) , 33-38
Effects of Dairy Products on the Oral Bioavailability of Moxifloxacin, a Novel 8-Methoxyfluoroquinolone, in Healthy Volunteers
Objective To investigate the effect of concomitant administration of dairy products on the pharmacokinetics and tolerability of moxifloxacin.
- 1 January 2001
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 40 (Supplement) , 33-38
Effects of Dairy Products on the Oral Bioavailability of Moxifloxacin, a Novel 8-Methoxyfluoroquinolone, in Healthy Volunteers
Objective To investigate the effect of concomitant administration of dairy products on the pharmacokinetics and tolerability of moxifloxacin.
- 1 January 2001
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 40 (Supplement) , 57-62
Effects of Iron Supplements on the Oral Bioavailability of Moxifloxacin, a Novel 8-Methoxyfluoroquinolone, in Humans
Objective To investigate the effect of concomitant iron administration on the pharmacokinetics and tolerability of moxifloxacin.
- 1 January 2001
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 40 (Supplement) , 57-62
Effects of Iron Supplements on the Oral Bioavailability of Moxifloxacin, a Novel 8-Methoxyfluoroquinolone, in Humans
Objective To investigate the effect of concomitant iron administration on the pharmacokinetics and tolerability of moxifloxacin.
- 1 January 2001
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 40 (Supplement) , 63-70
Lack of Pharmacokinetic Interaction between Moxifloxacin, a Novel 8-Methoxyfluoroquinolone, and Theophylline
Objective To investigate the plasma and urinary pharmacokinetics, safety and tolerability of theophylline and moxifloxacin after single and repeated doses of either compound administered alone or...
- 1 January 2001
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 40 (Supplement) , 63-70
Lack of Pharmacokinetic Interaction between Moxifloxacin, a Novel 8-Methoxyfluoroquinolone, and Theophylline
Objective To investigate the plasma and urinary pharmacokinetics, safety and tolerability of theophylline and moxifloxacin after single and repeated doses of either compound administered alone or...
- 1 January 2001
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 40 (1) , 71-76
Effect of Probenecid on the Kinetics of a Single Oral 400mg Dose of Moxifloxacin in Healthy Male Volunteers
- 1 January 2001
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 40 (1) , 71-76
Effect of Probenecid on the Kinetics of a Single Oral 400mg Dose of Moxifloxacin in Healthy Male Volunteers
- 1 January 2001
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 40 (Supplement) , 49-55
Effects of Sucralfate on the Oral Bioavailability of Moxifloxacin, a Novel 8-Methoxyfluoroquinolone, in Healthy Volunteers
To investigate the effect of concomitant Al3+ (sucralfate) administration on the pharmacokinetics and tolerability of moxifloxacin. This was a single-centre, randomised, nonblinded, 2-way crossover study in healthy volunteers. 12 healthy men (age 21 to 41 years) were enrolled in the study. The plasma and urinary pharmacokinetics of moxifloxacin were characterised up to 72 hours after single doses of moxifloxacin 400mg administered orally either alone or together with 190mg of Al3+ (Sucralfat-Ratiopharm® 1000) given immediately before and at 5, 10, 15 and 24 hours after the dose of moxifloxacin. There was a 2-week washout phase between the treatments. The treatments were well tolerated. The concomitant administration of Al3+ reduced the bioavailability of moxifloxacin [geometric mean area under the concentration-time curve from zero to infinity (AUC∞) 12.9 versus 32.2 mg/L · h; relative bioavailability 40%, 90% confidence interval (CI) 33 to 49%] and slowed down the absorption rate [median time to maximum concentration (tmax) 3.5 versus 1.0 hours], with a reduction of the maximum plasma concentration (Cmax) [geometric mean Cmax0.82 versus 2.83 mg/L; estimated true ratio of Cmax 29%, 90% CI 20 to 42%]. Concomitant ingestion with sucralfate and/or oral Al3+-containing antacids significantly reduces the bioavailability of moxifloxacin. This is compatible with reduced solubilisation as a consequence of a chelation reaction with polyvalent cations, a common finding for quinolones. Therefore, staggered administration of moxifloxacin and Al3+-containing or related cationic interactants should be considered to avoid a loss of therapeutic efficacy due to subtherapeutic plasma concentrations of the quinolone.
- 1 January 2001
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 40 (Supplement) , 49-55
Effects of Sucralfate on the Oral Bioavailability of Moxifloxacin, a Novel 8-Methoxyfluoroquinolone, in Healthy Volunteers
To investigate the effect of concomitant Al3+ (sucralfate) administration on the pharmacokinetics and tolerability of moxifloxacin. This was a single-centre, randomised, nonblinded, 2-way crossover study in healthy volunteers. 12 healthy men (age 21 to 41 years) were enrolled in the study. The plasma and urinary pharmacokinetics of moxifloxacin were characterised up to 72 hours after single doses of moxifloxacin 400mg administered orally either alone or together with 190mg of Al3+ (Sucralfat-Ratiopharm® 1000) given immediately before and at 5, 10, 15 and 24 hours after the dose of moxifloxacin. There was a 2-week washout phase between the treatments. The treatments were well tolerated. The concomitant administration of Al3+ reduced the bioavailability of moxifloxacin [geometric mean area under the concentration-time curve from zero to infinity (AUC∞) 12.9 versus 32.2 mg/L · h; relative bioavailability 40%, 90% confidence interval (CI) 33 to 49%] and slowed down the absorption rate [median time to maximum concentration (tmax) 3.5 versus 1.0 hours], with a reduction of the maximum plasma concentration (Cmax) [geometric mean Cmax0.82 versus 2.83 mg/L; estimated true ratio of Cmax 29%, 90% CI 20 to 42%]. Concomitant ingestion with sucralfate and/or oral Al3+-containing antacids significantly reduces the bioavailability of moxifloxacin. This is compatible with reduced solubilisation as a consequence of a chelation reaction with polyvalent cations, a common finding for quinolones. Therefore, staggered administration of moxifloxacin and Al3+-containing or related cationic interactants should be considered to avoid a loss of therapeutic efficacy due to subtherapeutic plasma concentrations of the quinolone.
- 1 January 2001
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 40 (Supplement) , 39-48
Evaluation of the Influence of Antacids and H2 Antagonists on the Absorption of Moxifloxacin after Oral Administration of a 400mg Dose to Healthy Volunteers
To determine the effect of concomitant administration of the antacid Maalox 70® or the histamine H2 receptor antagonist ranitidine on the bioavailability of moxifloxacin. These were nonblinded, randomised, crossover studies performed in healthy volunteers. 24 healthy males aged 22 to 39 years (study 1; n = 12) and 24 to 43 years (study 2; n = 12) were included in these studies. In study 1, 12 participants received ranitidine 150mg twice daily during a 3-day pretreatment phase and 1 tablet of ranitidine together with a single 400mg dose of moxifloxacin on the profile day. In study 2, 12 participants received a single 400mg dose of moxifloxacin alone (treatment A), simultaneously with Maalox 70® 10ml (treatment B), or with Maalox 70® 10ml given 4 hours before (treatment C) or 2 hours after (treatment D) the fluoroquinolone. In treatments B, C and D, administration of the antacid (10ml, 1 hour after each meal) was continued for 2 days. Plasma and urine samples were obtained for determination of the pharmacokinetic parameters of moxifloxacin. Coadministration of moxifloxacin with ranitidine showed lack of interaction for area under the plasma concentration-time curve extrapolated to infinity (AUC∞) [35.5 versus 34.3 mg/L · h with versus without ranitidine; relative bioavailability 103%, 90% confidence interval (CI) 97.7 to 109.3%] and maximum plasma concentration (Cmax) [2.98 versus 2.76 mg/L with versus without ranitidine; ratio 107.9%, 90% CI 90.5 to 128.6%]. When moxifloxacin was given simultaneously with Maalox 70®, AUC∞ (14.7 mg/L · h) and Cmax(1.00 mg/L) were reduced by approximately 60%. When the antacid was given 4 hours before or 2 hours after the fluoroquinolone, AUC∞ values (28.0 and 26.7 versus 34.3 mg/L · h) were moderately reduced (by max values were almost unchanged (2.55 and 2.38 versus 2.57 mg/L). The mean bioavailabilities corrected for the elimination rate constants (λz) were 101% (antacid given 4 hours before moxifloxacin) and 98% (antacid given 2 hours after moxifloxacin), indicating that Maalox 70® may interfere with the gastrointestinal recirculation of moxifloxacin. The bioavailability of moxifloxacin is not affected by concurrent administration of ranitidine. Absorption of moxifloxacin is impaired by concomitant administration of aluminium- and magnesium-containing antacids and administration of these agents should be staggered. An interval of 2 hours before or 4 hours after taking the antacid ensures that the effect of the interaction is not clinically relevant.
- 1 January 2001
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 40 (Supplement) , 39-48
Evaluation of the Influence of Antacids and H2 Antagonists on the Absorption of Moxifloxacin after Oral Administration of a 400mg Dose to Healthy Volunteers
To determine the effect of concomitant administration of the antacid Maalox 70® or the histamine H2 receptor antagonist ranitidine on the bioavailability of moxifloxacin. These were nonblinded, randomised, crossover studies performed in healthy volunteers. 24 healthy males aged 22 to 39 years (study 1; n = 12) and 24 to 43 years (study 2; n = 12) were included in these studies. In study 1, 12 participants received ranitidine 150mg twice daily during a 3-day pretreatment phase and 1 tablet of ranitidine together with a single 400mg dose of moxifloxacin on the profile day. In study 2, 12 participants received a single 400mg dose of moxifloxacin alone (treatment A), simultaneously with Maalox 70® 10ml (treatment B), or with Maalox 70® 10ml given 4 hours before (treatment C) or 2 hours after (treatment D) the fluoroquinolone. In treatments B, C and D, administration of the antacid (10ml, 1 hour after each meal) was continued for 2 days. Plasma and urine samples were obtained for determination of the pharmacokinetic parameters of moxifloxacin. Coadministration of moxifloxacin with ranitidine showed lack of interaction for area under the plasma concentration-time curve extrapolated to infinity (AUC∞) [35.5 versus 34.3 mg/L · h with versus without ranitidine; relative bioavailability 103%, 90% confidence interval (CI) 97.7 to 109.3%] and maximum plasma concentration (Cmax) [2.98 versus 2.76 mg/L with versus without ranitidine; ratio 107.9%, 90% CI 90.5 to 128.6%]. When moxifloxacin was given simultaneously with Maalox 70®, AUC∞ (14.7 mg/L · h) and Cmax(1.00 mg/L) were reduced by approximately 60%. When the antacid was given 4 hours before or 2 hours after the fluoroquinolone, AUC∞ values (28.0 and 26.7 versus 34.3 mg/L · h) were moderately reduced (by max values were almost unchanged (2.55 and 2.38 versus 2.57 mg/L). The mean bioavailabilities corrected for the elimination rate constants (λz) were 101% (antacid given 4 hours before moxifloxacin) and 98% (antacid given 2 hours after moxifloxacin), indicating that Maalox 70® may interfere with the gastrointestinal recirculation of moxifloxacin. The bioavailability of moxifloxacin is not affected by concurrent administration of ranitidine. Absorption of moxifloxacin is impaired by concomitant administration of aluminium- and magnesium-containing antacids and administration of these agents should be staggered. An interval of 2 hours before or 4 hours after taking the antacid ensures that the effect of the interaction is not clinically relevant.